UA107186C2 - SOLID FORMS OF BENDAMUSTINE DOSAGE - Google Patents

SOLID FORMS OF BENDAMUSTINE DOSAGE

Info

Publication number
UA107186C2
UA107186C2 UAA201106236A UAA201106236A UA107186C2 UA 107186 C2 UA107186 C2 UA 107186C2 UA A201106236 A UAA201106236 A UA A201106236A UA A201106236 A UAA201106236 A UA A201106236A UA 107186 C2 UA107186 C2 UA 107186C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutically acceptable
saccharide
polysaccharide
tablets
disaccharide
Prior art date
Application number
UAA201106236A
Other languages
Russian (ru)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to UAA201404416A priority Critical patent/UA116334C2/en
Publication of UA107186C2 publication Critical patent/UA107186C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Винахід стосується фармацевтичної композиції у твердій формі дозування для перорального призначення, яка містить як активний інгредієнт бендамустин або його фармацевтично прийнятний естер, сіль або сольват та принаймні один фармацевтично прийнятний наповнювач, яким є фармацевтично прийнятний сахарид, вибраний з одного або більше: моносахариду, дисахариду, олігосахариду, циклічного олігосахариду, полісахариду та сахаридного спирту, де співвідношення мас активного інгредієнта відносно сахаридного наповнювача є у межах 1:1-5, та в якому композиція є у формі таблеток, гранулятів або пігулок, та де полісахарид не є мікрокристалічною целюлозою, якщо сахаридний спирт є тільки манітолом.The invention relates to a pharmaceutical composition in solid dosage form for oral administration containing as an active ingredient bendamustine or its pharmaceutically acceptable ester, salt or solvate and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from one or more: monosaccharide, disaccharide, disaccharide oligosaccharide, cyclic oligosaccharide, polysaccharide and saccharide alcohol, where the mass ratio of the active ingredient to the saccharide filler is in the range 1: 1-5, and in which ompozytsiya is in the form of tablets, granules or tablets, and where the polysaccharide is not microcrystalline cellulose, if only Carbohydrate alcohol is mannitol.

UAA201106236A 2008-12-03 2009-03-12 SOLID FORMS OF BENDAMUSTINE DOSAGE UA107186C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAA201404416A UA116334C2 (en) 2008-12-03 2009-12-03 SOLID FORMS OF BENDAMUSTINE DOSAGE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08020996 2008-12-03
PCT/EP2009/008639 WO2010063476A2 (en) 2008-12-03 2009-12-03 Solid dosage forms of bendamustine

Publications (1)

Publication Number Publication Date
UA107186C2 true UA107186C2 (en) 2014-12-10

Family

ID=40588072

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201106236A UA107186C2 (en) 2008-12-03 2009-03-12 SOLID FORMS OF BENDAMUSTINE DOSAGE
UAA201404416A UA116334C2 (en) 2008-12-03 2009-12-03 SOLID FORMS OF BENDAMUSTINE DOSAGE

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201404416A UA116334C2 (en) 2008-12-03 2009-12-03 SOLID FORMS OF BENDAMUSTINE DOSAGE

Country Status (26)

Country Link
US (4) US20120003309A1 (en)
EP (1) EP2367538B1 (en)
JP (3) JP5658679B2 (en)
KR (1) KR101710935B1 (en)
CN (2) CN107080742B (en)
AU (1) AU2009321728B2 (en)
BR (1) BRPI0922804B8 (en)
CA (1) CA2745509A1 (en)
CO (1) CO6400185A2 (en)
CY (1) CY1119839T1 (en)
DK (1) DK2367538T3 (en)
EA (1) EA028179B1 (en)
ES (1) ES2645008T3 (en)
HR (1) HRP20171421T1 (en)
HU (1) HUE036481T2 (en)
IL (1) IL213269A (en)
LT (1) LT2367538T (en)
MX (1) MX2011005633A (en)
NZ (1) NZ592971A (en)
PL (1) PL2367538T3 (en)
PT (1) PT2367538T (en)
RS (1) RS56408B1 (en)
SI (1) SI2367538T1 (en)
UA (2) UA107186C2 (en)
WO (1) WO2010063476A2 (en)
ZA (1) ZA201103790B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107186C2 (en) * 2008-12-03 2014-12-10 SOLID FORMS OF BENDAMUSTINE DOSAGE
MY173873A (en) * 2010-06-02 2020-02-25 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
JO3659B1 (en) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh Oral dosage forms of bendamustine and therapeutic use thereof
CN102375044B (en) * 2010-08-18 2015-04-08 重庆华邦胜凯制药有限公司 Method for analyzing related substance from hydrochloric acid bendamustine intermediate Z6
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
JP2016153374A (en) * 2013-06-25 2016-08-25 シンバイオ製薬株式会社 Pharmaceutical composition for treating or preventing inflammatory disease
CA2922099C (en) 2013-08-27 2022-11-29 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
CN105566226B (en) * 2014-05-06 2019-06-21 南京先声东元制药有限公司 The preparation method and application of bendamustine hydrochloride dimer
JP6608193B2 (en) * 2014-06-27 2019-11-20 花王株式会社 Solid composition
WO2016005995A2 (en) * 2014-07-10 2016-01-14 Leiutis Pharmaceuticals Pvt. Ltd. Glycol free stable liquid compositions of bendamustine
JP5897196B1 (en) * 2015-10-05 2016-03-30 大同化成工業株式会社 Compound granulated product containing sugar or sugar alcohol, swelling binder, disintegrant and superabsorbent excipient, and production method thereof
EP3691637A1 (en) 2017-10-05 2020-08-12 TUBE Pharmaceuticals GmbH Oral bendamustine formulations
CN110437261A (en) * 2018-05-02 2019-11-12 南京诺瑞特医药科技有限公司 The synthetic method of bendamustine impurity G
CN113768038A (en) * 2021-09-14 2021-12-10 江苏省协同医药生物工程有限责任公司 Accurate quantitative experimental animal functional feed and preparation method and equipment
CN117257913B (en) * 2023-11-23 2024-01-26 江西中医药大学附属医院 Lung-warming chemical fiber granule and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CA2585659A1 (en) * 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (en) * 2008-03-26 2010-09-22 Cephalon Inc SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE
UA107186C2 (en) * 2008-12-03 2014-12-10 SOLID FORMS OF BENDAMUSTINE DOSAGE

Also Published As

Publication number Publication date
CA2745509A1 (en) 2010-06-10
JP5658679B2 (en) 2015-01-28
PL2367538T3 (en) 2017-12-29
MX2011005633A (en) 2011-09-27
CN107080742A (en) 2017-08-22
EP2367538B1 (en) 2017-08-02
BRPI0922804A2 (en) 2015-12-22
IL213269A (en) 2017-04-30
DK2367538T3 (en) 2017-10-02
EP2367538A2 (en) 2011-09-28
UA116334C2 (en) 2018-03-12
KR20110102392A (en) 2011-09-16
BRPI0922804B8 (en) 2021-05-25
HUE036481T2 (en) 2018-07-30
EA028179B1 (en) 2017-10-31
CN102292073B (en) 2018-07-10
ZA201103790B (en) 2012-08-29
SI2367538T1 (en) 2017-11-30
KR101710935B1 (en) 2017-02-28
NZ592971A (en) 2013-08-30
JP2017057225A (en) 2017-03-23
US20170100376A1 (en) 2017-04-13
HRP20171421T1 (en) 2017-11-03
CY1119839T1 (en) 2018-06-27
CO6400185A2 (en) 2012-03-15
JP2012510483A (en) 2012-05-10
AU2009321728B2 (en) 2016-07-07
BRPI0922804B1 (en) 2020-11-17
CN107080742B (en) 2020-08-18
US11160793B2 (en) 2021-11-02
US20120003309A1 (en) 2012-01-05
CN102292073A (en) 2011-12-21
LT2367538T (en) 2017-12-27
RS56408B1 (en) 2018-01-31
WO2010063476A2 (en) 2010-06-10
JP2015061864A (en) 2015-04-02
IL213269A0 (en) 2011-07-31
AU2009321728A1 (en) 2011-06-30
US20140004190A1 (en) 2014-01-02
EA201190012A1 (en) 2012-02-28
BRPI0922804A8 (en) 2017-12-26
ES2645008T3 (en) 2017-12-01
PT2367538T (en) 2017-11-14
WO2010063476A3 (en) 2010-08-05
US20160106716A1 (en) 2016-04-21
JP6396980B2 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
UA107186C2 (en) SOLID FORMS OF BENDAMUSTINE DOSAGE
ATE493972T1 (en) JOINTLY PROCESSED MICROCRYSTALLINE CELLULOSE AND SUGAR ALCOHOL AS AN EXCIPIENT FOR TABLET FORMULATIONS
IL195732A (en) Pharmaceutical compositions comprising fesoterodine, use thereof and method for its preparation
NZ591710A (en) Controlled release oral dosage form comprising at least one portion that is rapidly disintegrating and at least one portion that is slowly disintegrating
JO3659B1 (en) Oral dosage forms of bendamustine and therapeutic use thereof
HRP20200850T1 (en) Orodispersible dosage unit containing an estetrol component
NZ611467A (en) Rapidly dispersing granules, orally disintegrating tablets and methods
JP2011157401A5 (en)
MX337603B (en) Compressible-coated pharmaceutical compositions and tablets and methods of manufacture.
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
AR074739A1 (en) FAST DISGREGATION CAPECITABIN TABLETS
NO20074933L (en) Pharmaceutical composition comprising an indolylmaleimide derivative
IL291562B2 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
RU2007107368A (en) COMPOSITION CONTAINING DESMOPRESSIN
HRP20151321T1 (en) Modified release compositions of epalrestat or a derivative thereof and methods for using the same
TNSN08528A1 (en) Galenical formulations of aliskiren and hydrochlorothiazide
NO331205B1 (en) Pharmaceutical composition as solid dosage form and method of preparation thereof
GB2448430A (en) Synergistic binder composition, method for making same and tablets of an active and said binder having advantageous hardness and friability
UA94107C2 (en) Stabilized pharmaceutical composition comprising fesoterodine
RU2013118917A (en) MEDICINAL FORM CONTAINING DESLORATADINE AND METHOD FOR PRODUCING IT
RU2013155510A (en) PHARMACEUTICAL COMPOSITION OF N- (6-PHENYLHEXANOYL) GLYCYL-TRIPTOPHANE AMID COMPLETED IN A SOLID MEDICINAL FORM AND METHODS FOR PRODUCING IT
WO2012052178A3 (en) Improved pharmaceutical starter pellets
UA47107U (en) Drug formulation in tablet form possessing mucolytic and antihistamine properties